Extensive, late-stage radiopharmaceutical pipeline

Our core product pipeline, focused on urologic oncology (prostate, kidney and bladder), neuro-oncology (glioma), musculoskeletal oncology (sarcoma) and hematology, has generated extensive clinical data that demonstrate the potential for efficacy and acceptable safety profile. We believe the targets and indications we are pursuing are well validated and are well suited for the delivery of therapeutic and diagnostic targeted radiation. The use of imaging to select patients for therapy is also a differentiated aspect of our commercial strategy.

Late-stage therapeutic pipeline

Targeting
agent
Isotope
Phase 1
Phase 2
Phase 3
Prostate
PSMA1
Antibody
177Lu
TLX591 (177Lu rosopatamab tetraxetan)
Kidney + other
CAIX2
Antibody
177Lu
TLX250 (177Lu-girentuximab)
Brain
LAT4
Small molecule
131I
TLX101 (131I-IPA)
Hematology
CD667
Antibody
90Y
TLX66 (90Y-besilesomab), CD66 targeting candidate for bone-marrow conditioning

Early-stage therapeutic pipeline

Targeting
agent
Isotope
R&D
Pre clinical
Clinical (Ph 0/1)
Prostate
PSMA
Antibody
225Ac (alpha)
TLX592 (225Ac-RADmAb®)
Kidney + other
CAIX
Antibody
225Ac (alpha)
TLX252 (225Ac-girentuximab)
Bladder
FAP
Small molecule
Undisclosed
TLX400 (New in-license)
Brain
LAT
Small molecule
211At (alpha)
TLX102 (211At-APA)
Musculoskeletal
Antibody
Undisclosed
TLX300 (-olaratumab), PDGFRα6 targeting candidate for soft tissue sarcoma
Musculoskeletal
Small molecule
153Sm
TLX090 (153Sm-DOTMP), bone-seeking agent for bone metastases and pain palliation

Precision medicine portfolio

Targeting
agent
Isotope
Pre-clinical
Phase 1
Phase 2
Phase 3
Commercial
Prostate
PSMA
Small molecule
68Ga
Illuccix® (68Ga-PSMA-11)
Prostate
PSMA
Small molecule
68Ga
Gozellix® (68Ga-PSMA-11)
Kidney + other
CAIX
Antibody
89Zr
TLX250-CDx, Zircaix®3 (89Zr-girentuximab)
Brain
LAT
Small molecule
18F
TLX101-CDx, Pixclara®3 (18F-floretyrosine)
Musculoskeletal
Antibody
99mTc
TLX66-CDx (99mTc-besilesomab, Scintimun®), CD66 imaging agent for osteomyelitis (bone infection)

1. Prostate-specific membrane antigen.
2. Carbonic anhydrase IX.
3. Trade name subject to final regulatory approval.
4. Large amino acid transporters 1 and 2.
5. Soft tissue sarcoma.
6. Platelet derived growth factor receptor alpha.
7. Cluster of differentiation 66.